Category: Batten disease

  • Amicus rejiggers gene therapy plans as SPAC merger folds in unfriendly market

    The SPAC merger that Amicus Therapeutics planned for its gene therapy assets has been called off due to market conditions. The rare disease company is instead keeping those assets but streamlining its portfolio in order to save $400 million—the amount that the gene therapy spinout was in line to receive from the merger deal.